Comprehensive Care of Patients with Chronic Liver Disease

Medical Clinics of North America

Volumn 99, Issue 5, 2015, Pages 913-933

  James, Jocelyn ^a   Liou, Iris W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Chronic liver disease; Cirrhosis; Hepatic encephalopathy; Spontaneous bacterial peritonitis; Varices

Indexed keywords

AMFEBUTAMONE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULOXETINE; LAMOTRIGINE; MACROLIDE; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENYTOIN; PYRROLE DERIVATIVE; TETRACYCLINE DERIVATIVE; VALPROIC ACID;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ASCITES; BODY WEIGHT MANAGEMENT; CANCER SCREENING; CANNABIS USE; CHILD PUGH SCORE; CHRONIC HEPATITIS B; CHRONIC LIVER DISEASE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG SAFETY; ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; EXERCISE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATOGRAPHY; HUMAN; JAUNDICE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NUTRITION EDUCATION; OSTEOPENIA; OSTEOPOROSIS; PALLIATIVE THERAPY; PARACENTESIS; PATIENT COUNSELING; PATIENT MONITORING; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN CALORIE MALNUTRITION; PROTEIN INTAKE; REVIEW; RISK REDUCTION; SMOKING; SURGICAL RISK; TERMINAL CARE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VARICOSIS; VIRUS TRANSMISSION; WILSON DISEASE; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COMPLICATION; DISEASE MANAGEMENT; EARLY DIAGNOSIS; ESOPHAGEAL AND GASTRIC VARICES; LIVER DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; DISEASE MANAGEMENT; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; ESOPHAGEAL AND GASTRIC VARICES; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER DISEASES; MONITORING, PHYSIOLOGIC; PROGNOSIS;

EID: 84940614792     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2015.05.001     Document Type: Review

References (52)

1. Deaths: final data for 2010. National Vital Statistics Reports. Available at: . http://cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf.
2. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.
3. Mendenhall C., Roselle G.A., Gartside P., et al. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995, 19(3):635-641.
4. Caregaro L., Alberino F., Amodio P., et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996, 63(4):602-609.
5. Swart G.R., Zillikens M.C., van Vuure J.K., et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ 1989, 299(6709):1202-1203.
6. Gramlich L., Tandon P., Rahman A. Nutritional status in patients with sustained heavy alcohol use 2014, Up To Date, Waltham (MA), Available at:, Accessed September, 2014. http://www.uptodate.com/contents/nutritional-status-in-patients-with-sustained-heavy-alcohol-use.
7. Roberts E.A., Schilsky M.L., American Association for Study of Liver Diseases (AASLD) Diagnosis and treatment of Wilson disease: an update. Hepatology 2008, 47(6):2089-2111.
8. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27(1):103-107.
9. Everhart J.E., Lok A.S., Kim H.Y., et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009, 137(2):549-557.
10. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142(1):37-46.
11. Bjelakovic G., Nikolova D., Gluud L.L., et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297(8):842-857.
12. Klein E.A., Thompson I.M., Tangen C.M., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306(14):1549-1556.
13. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012, 142(7):1592-1609.
14. Thun M.J., Peto R., Lopez A.D., et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997, 337(24):1705-1714.
15. Corrao G., Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998, 27(4):914-919.
16. Pessione F., Ramond M.J., Peters L., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003, 23(1):45-53.
17. Jonas D.E., Amick H.R., Feltner C., et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014, 311(18):1889-1900.
18. Hezode C., Lonjon I., Roudot-Thoraval F., et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003, 52(1):126-129.
19. Hezode C., Zafrani E.S., Roudot-Thoraval F., et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008, 134(2):432-439.
20. Dominguez M., Barcena R., Garcia M., et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000, 6(4):440-442.
21. Carey E.J., Balan V., Kremers W.K., et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 2003, 9(11):1166-1173.
22. Susan Ott. In: James J, editor. Patient documentation. 2014.
23. Mansour A., Watson W., Shayani V., et al. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997, 122(4):730-735. [discussion: 735-6].
24. Farnsworth N., Fagan S.P., Berger D.H., et al. Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 2004, 188(5):580-583.
25. Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013, 158(11):807-820.
26. Berzigotti A., Ashkenazi E., Reverter E., et al. Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011, 31(3):129-138.
27. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
28. El-Serag H.B., Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?. Hepatology 2014, 60(5):1767-1775.
29. Bruix J., Sherman M., Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
30. Bruix J., Sherman M., American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
31. Lok A.S., Sterling R.K., Everhart J.E., et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138(2):493-502.
32. Runyon B.A. Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med 1986, 146(11):2259-2261.
33. Gines P., Arroyo V., Quintero E., et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987, 93(2):234-241.
34. Heuman D.M., Abou-Assi S.G., Habib A., et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004, 40(4):802-810.
35. Bernardi M., Caraceni P., Navickis R.J., et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55(4):1172-1181.
36. Gines P., Uriz J., Calahorra B., et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123(6):1839-1847.
37. Evans L.T., Kim W.R., Poterucha J.J., et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003, 37(4):897-901.
38. Gines P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990, 12(4 Pt 1):716-724.
39. Garcia-Tsao G., Sanyal A.J., Grace N.D., Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46(3):922-938.
40. Bosch J., Garcia-Pagan J.C. Prevention of variceal rebleeding. Lancet 2003, 361(9361):952-954.
41. Gonzalez R., Zamora J., Gomez-Camarero J., et al. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008, 149(2):109-122.
42. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):3-9.
43. Ong J.P., Aggarwal A., Krieger D., et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003, 114(3):188-193.
44. Vilstrup H., Amodio P., Bajaj J., et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014, 60(2):715-735.
45. Bajaj J.S., Sanyal A.J., Bell D., et al. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010, 31(9):1012-1017.
46. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362(12):1071-1081.
47. Plauth M., Cabre E., Riggio O., et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006, 25(2):285-294.
48. D'Amico G., Garcia-Tsao G., Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006, 44(1):217-231.
49. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001, 33(2):464-470.
50. Gines P., Quintero E., Arroyo V., et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987, 7(1):122-128.
51. Fede G., D'Amico G., Arvaniti V., et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol 2012, 56(4):810-818.
52. Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010, 139(4):1246-1256. 1256.e1-5.